Amicus Therapeutics (NASDAQ:FOLD) reported quarterly sales of $88.10 million which beat the analyst consensus estimate of $86.29 million by 2.09 percent. This is a 7.23 percent increase over sales of $82.15 million the same period last year.
Portillos’s Return on Invested Capital Overview
According to Benzinga Pro, during Q2, Portillos (NASDAQ:PTLO) earned $10.76 million, a 1855.64% increase from the preceding quarter. Portillos also posted a total of $150.62 million in sales, a 12.0% increase since Q1.
